CPT code 87631 represents a multiplex nucleic acid-based laboratory test that detects three to five respiratory pathogens or subtypes, using amplified probe techniques with multiplex reverse transcription when applicable. This category of molecular diagnostic testing is clinically important for identifying viral causes of acute respiratory infections, guiding infection control measures, appropriate antiviral use, and cohorting decisions in healthcare settings. Nationally, such tests support surveillance and clinical decision-making across outpatient clinics, emergency departments, and hospital laboratories.

Key payers addressed in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find a concise overview of clinical context for multiplex respiratory panels, common billing and coding considerations specific to CPT code 87631, and payer coverage patterns where available. The publication summarizes typical sites of service and service classification, highlights common modifiers associated with laboratory services (listed separately), and outlines benchmarking topics and policy developments that affect reimbursement and utilization of respiratory pathogen panels.

This resource is intended to inform billing staff, laboratory managers, and health policy stakeholders about the scope and clinical role of CPT code 87631, plus the payer landscape and areas where policy changes may influence adoption and payment practices. Data not available in the input is noted where applicable.